Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice Concerning the Designation of a Suspension of Exercise of the 19th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause)

For the 19th Series of Stock Acquisition Rights allocated to EVO FUND, a period during which exercise would be suspended was designated from 19 November to 18 December 2026. The designation covers all stock acquisition rights remaining outstanding as of the start date.

Worth reading
59In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
4280000
Shares (remaining unexercised portion)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)

Intended allottee
EVO FUND (the allottee to which the rights have been allocated, as described in this document)
Terms of the stock acquisition rights
Exercise price
Only the inclusion of an exercise price adjustment clause is disclosed. The adjustment floor is Not disclosed
Number of Stock Acquisition Rights
Total number issued: Not disclosed; remaining unexercised: 42,800 units (4,280,000 shares)
Most recent equity financing
Announced 27 May 2026: issuance through a third-party allotment of the 19th Series of Stock Acquisition Rights with an exercise price adjustment clause and the 2nd Series of Unsecured Bonds (privately placed), and execution of a purchase agreement for the stock acquisition rights
Details of issuance or disposal
ItemDetails
Type of issuance or disposal19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
Intended allotteeEVO FUND (the allottee to which the rights have been allocated, as described in this document)
Exercise priceOnly the inclusion of an exercise price adjustment clause is disclosed. The adjustment floor is Not disclosed
Number of Stock Acquisition RightsTotal number issued: Not disclosed; remaining unexercised: 42,800 units (4,280,000 shares)
Most recent equity financingAnnounced 27 May 2026: issuance through a third-party allotment of the 19th Series of Stock Acquisition Rights with an exercise price adjustment clause and the 2nd Series of Unsecured Bonds (privately placed), and execution of a purchase agreement for the stock acquisition rights
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To comprehensively consider the company's business progress, funding needs and market conditions, among other factors, and to limit significant dilution of shareholder value occurring at one time.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Designation of a Suspension of Exercise of the 19th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori